Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Improvement of H. Pylori eradication therapy efficiency in patients with ischemic heart disease

[Original research]
Natalia Kireeva; Andrey Svistunov; Mikhail Osadchuk;

In 110 patients with chronic atrophic gastritis associated with Helicobacter pylori against the background of hypercholesterolemia and exertional angina of functional class I–II study of the efficiency of eradication therapy has been conducted. Our results suggest a significant role for the level of blood cholesterol in the formation of antibiotic resistance during H. pylori eradication. Normalization of cholesterol levels increased the effectiveness of treatment, which makes it reasonable to use statins during eradication of H. pylori in chronic atrophic gastritis.


1. Tepes B., Kastelic M., Vujasinovic M., Lampic P., Seruga M. [et al.]. Helicobacter pylori treatment results in
Slovenia in the period 2013–2015 as a part of European Registry on Helicobacter pylori Management. Radiol Oncol. 2017;52(1):1-6. https://doi.org/10.1515/raon-2017-0055
2. Papastergiou V., Mathou N., Licousi S., Evgenidi A., Paraskeva K. D. [et al.]. Seven-day genotypic resistanceguided triple Helicobacter pylori eradication therapy can be highly effective. Ann. Gastroenterol. 2018;31(1):1-7. https://dx.doi.org/10.20524/aog.2017.0219
3. Malfertheiner P., Megraud F., O’morain C. A., Gisbert J. P., Kuipers E. J. [et al.]. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report.Gut. 2016;66(1):6-30. https://doi.org/10.1136/gutjnl-2016-312288
4. Liou J., Chen C., Chen M., Chen C., Chang C. [et al.]. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. The Lancet. 2013;381(9862):205-213. https://doi.org/10.1016/s0140-6736(12)61579-7
5. Thung I., Aramin H., Vavinskaya V., Gupta S., Park J. [et al.]. Review article: the global emergence ofHelicobacter pyloriantibiotic resistance. Aliment. Pharmacol. Ther. 2015;43(4):514-533. https://doi.org/10.1111/apt.13497
6. Papastergiou V., Georgopoulos S. D., Karatapanis S. Treatment of Helicobacter pylori infection: meeting the
challenge of antimicrobial resistance. World J. Gastroenterol. 2014;20(29):9898. https://doi.org/10.3748/wjg.v20.i29.9898
7. Wang J., Tseng K., Hsu C., Liang C., Tai W. [et al.]. Association between Helicobacter pylori eradication
and the risk of coronary heart diseases. PLoS ONE. 2018;13(1):e0190219. https://doi.org/10.1371/journal.pone.0190219
8. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H.pylori specific DNA in human coronary atherosclerotic plaque. J. Physiol. Pharmacol. 2001;52(1):3-31.
9. Kang J. M., Kim N., Shin C. M., Lee H. S., Lee D. H. [et al.]. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after helicobacter pylori eradication: a three-year follow-up study in Korea. Helicobacter. 2012;17(2):86-95. https://doi.org/10.1111/j.1523-5378.2011.00918.x
10. Kodama M., Murakami K., Okimoto T., Abe T., Nakagawa Y. [et al.]. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion. 2012;85:126-130. https://doi.org/10.1159/000334684
11. Liao W. C., Huang M. Z., Wang M. L., Lin C. J., Lu T. L. [et al.]. Statin decreases Helicobacter pylori burden in macrophages by promoting autophagy. Front Cell Infect Microbiol. 2017;6. Availibale at: ww.frontiersin.org/article/10.3389/fcimb.2016.00203. Accessed March 2, 2019.
12. Wunder C., Churin Y., Winau F., Warnecke D., Vieth M. [et al.]. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat. Med. 2006;12(9):1030-1038. https://doi.org/10.1038/nm1480
13. Murata-Kamiya N., Kikuchi K., Hayashi T., Higashi H., Hatakeyama M. Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein. Cell. Host. Microbe. 2010;7(5):399-411. https://doi.org/10.1016/j.chom.2010.04.005
14. Lai C. H., Hsu Y. M., Wang H. J., Wang W. C. Manipulation of host cholesterol by Helicobacter pylori for their beneficial ecological niche. Biomedicine (Taipei). 2013;3(1):27-33. https://doi.org/10.1016/j.biomed.2012.12.002
15. Lai C., Wang H., Chang Y., Hsieh W., Lin H. [et al.]. Helicobacter pylori CagA-mediated IL-8 induction in gastric epithelial cells is cholesterol-dependent and requires the C-terminal tyrosine phosphorylation-containing domain. FEMS Microbiol. Lett. 2011;323(2):155-163. https://doi.org/10.1111/j.1574-6968.2011.02372.x
16. Wang H. J., Cheng W. C., Cheng H. H., Lai C. H., Wang W. C. Helicobacter pylori cholesteryl glucosides interfere with host membrane phase and affect type IV secretion system function during infection in AGS cells. Mol. Microbiol. 2011;83(1):67-84. https://doi.org/10.1111/j.1365-2958.2011.07910.x
17. Terebiznik M., Raju D., Vázquez C., Torbricki K., Kulkarni R. [et al.]. Effect of Helicobacter pylori’s vacuolating cytotoxin on the autophagy pathway in gastric epithelial cells. Autophagy. 2009;5(3):370-379.
18. Wang Y. H., Wu J. J., Lei H. Y. The autophagic induction in Helicobacter pylori-infected macrophage. Exper. Biol. Med. 2009;234(2):171-180. https://doi.org/10.3181/0808-rm-252
19. Cheng J., Ohsaki Y., Tauchi-Sato K., Fujita A., Fujimoto T. Cholesterol depletion induces autophagy. Biochem. Biophys. Res. Commun. 2006;351(1):246-252. https://doi.org/10.1016/j.bbrc.2006.10.042
20. Deretic V., Saitoh T., Akira S. Autophagy in infection, inflammation and immunity. Nature Reviews Immunology. 2013;13(10):722-737. https://doi.org/10.1038/nri3532
21. Lai C., Su J., Lin Y., Chang C., Feng C. [et al.]. Involvement of cholesterol in Campylobacter jejuni cytolethal distending toxin-induced pathogenesis. Future Microbiol. 2015;10(4):489-501. https://doi.org/10.2217/fmb.14.119
22. Alzahrani S., Lina T. T., Gonzalez J., Pinchuk I. V., Beswick E. J., Reyes V. E. Effect of Helicobacter pylori on gastric epithelial cells. World J. Gastroenterol. 2014;20(36):12767. https://doi.org/10.3748/wjg.v20.i36.12767
23. Ashktorab H., Dashwood R., Dashwood M., Zaidi S., Hewitt S. [et al.]. H.pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria. Helicobacter. 2008;13(6):506-517. https://doi.org/10.1111/j.1523-5378.2008.00646.x
24. Beswick E. J., Pinchuk I. V., Suarez G., Sierra J. C., Reyes V. E. Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J. Immunol. 2006;176(11):6794-6801.https://doi.org/10.4049/jimmunol.176.11.6794
25. Ayed D. B., Khabir A., Abid M., Bayrouti M. I., Gargouri A. [et al.]. Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas. Acta Histochem. 2014;116(8):1244-1250. https://doi.org/10.1016/j.acthis.2014.07.008

Keywords: ischemic heart disease, H. pylori eradication, cholesterol, statins

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy